Signadori Bio

Signadori Bio is a preclinical-stage biopharmaceutical company that emerged in 2025 as a strategic collaboration between the European life sciences venture capital firm Sofinnova Partners and Gustave Roussy, a premier cancer center in Europe. The company was established with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, leveraging their research conducted at Gustave Roussy. The venture is steered by CEO Matthieu Coutet, who is also a Partner at Sofinnova Partners.

The firm is focused on developing a next-generation cell therapy platform to address the complexities of treating solid tumors. Signadori Bio's core technology centers on a monocyte-based cell therapy approach. This involves harnessing the immune potential of gene-modified monocytes and macrophages to overcome the challenging tumor microenvironment. The company's business model is centered on advancing its proprietary platform from the preclinical stage through to clinical trials and eventual commercialization. As a venture capital-backed entity, its operations are financed through strategic investments. In March 2025, it was announced as one of the first companies to receive investment from Sofinnova's €165 million Biovelocita II fund, which is supported by major pharmaceutical players like Amgen and Bristol Myers Squibb. Invivo Partners also joined as an investor, further strengthening the company's financial and strategic foundation.

Headquartered in Paris, France, Signadori Bio is currently in the preclinical stage of development. A significant milestone was the establishment of a partnership with eXmoor Pharma in June 2025 to accelerate the development and manufacturing of its lead candidate. This collaboration is designed to guide the therapy program through critical development milestones, with a long-term goal of GMP-compliant manufacturing for first-in-human clinical trials. The company aims to make more information public as it moves out of stealth mode.

Keywords: cell therapy, oncology, solid tumors, biopharmaceutical, preclinical, Gustave Roussy, Sofinnova Partners, Invivo Partners, monocyte-based therapy, gene-modified monocytes, cancer treatment, immunotherapy, macrophage cell therapy, venture capital, HealthTech, Life Sciences, biotherapeutics, translational science, drug development, gene therapy